CN1340360A - Immunoactive yolk-albumen composition - Google Patents
Immunoactive yolk-albumen composition Download PDFInfo
- Publication number
- CN1340360A CN1340360A CN 00125941 CN00125941A CN1340360A CN 1340360 A CN1340360 A CN 1340360A CN 00125941 CN00125941 CN 00125941 CN 00125941 A CN00125941 A CN 00125941A CN 1340360 A CN1340360 A CN 1340360A
- Authority
- CN
- China
- Prior art keywords
- complex
- enterotoxin
- immunoglobulin
- lysozyme
- ovotransferrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 12
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 12
- 102000016943 Muramidase Human genes 0.000 claims abstract description 9
- 108010014251 Muramidase Proteins 0.000 claims abstract description 9
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 9
- 229960000274 lysozyme Drugs 0.000 claims abstract description 9
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 9
- 239000004325 lysozyme Substances 0.000 claims abstract description 9
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 7
- 239000011573 trace mineral Substances 0.000 claims abstract description 7
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 3
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 3
- 239000000147 enterotoxin Substances 0.000 claims description 13
- 108010026206 Conalbumin Proteins 0.000 claims description 8
- 235000013601 eggs Nutrition 0.000 claims description 4
- 101710146739 Enterotoxin Proteins 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 231100000655 enterotoxin Toxicity 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 235000013345 egg yolk Nutrition 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000005189 flocculation Methods 0.000 claims description 2
- 230000016615 flocculation Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000001471 micro-filtration Methods 0.000 claims description 2
- 230000000474 nursing effect Effects 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 208000035240 Disease Resistance Diseases 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002956 ash Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 210000004681 ovum Anatomy 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- -1 iron ion Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
An immunoactive yolk-albumen composition for supplementing nutrients to human body, suppressing the pathogenic bacteria in intestinal tract and improving disease resistance contains antienterotoxin immunoglobulin (45-55 wt.%), ovum converted Fe protein (17-23), lysozyme (17-23), and the rest being water, ash and trace elements. The said antienterotoxin immunoglobulin has molecular weigh of 172 KD and is composed of two heavy chains and two light chains.
Description
The present invention relates to protein complex.
Egg nutrient is worth high, and edible back is to replenishing the human nutrition element, and health invigorating is beneficial.But people do not extract a kind of material with higher effect as yet from egg so far, and this material element that can supplement the nutrients can suppress, engulf the pathogenic bacteria in the intestinal again.Also unprecedented this complex of the present invention in the known technology.
The object of the present invention is to provide a kind of contain several amino acids and trace element, can suppress after edible, the crystal type albumen composition of the interior pathogenic bacteria of phagosome.
Its special character of technical solution of the present invention is to contain following component: anti-enterotoxin immunoglobulin, ovotransferrin and lysozyme.
Complex of the present invention contains moisture, ash and the trace element of anti-enterotoxin immunoglobulin 45～55%, ovotransferrin 17～23%, lysozyme 17～23% and surplus in its gross weight.
Described complex is in its gross weight, and preferred ingredients content is moisture, ash and the trace element of anti-enterotoxin immunoglobulin 50%, ovotransferrin 20%, lysozyme 20% and surplus.
Complex of the present invention, described its molecular structure pattern of anti-enterotoxin immunoglobulin is:
Its molecular weight is 172KD (1720000), is 2 heavy chain H and 2 light chain L, becomes the Y font, light chain L molecular weight～23KD (230000) wherein, heavy chain H molecular weight～63KD (630000).
Complex of the present invention is produced through the method: adopt the cell bacterium of enterotoxin class to make antigen, be prepared into vaccine, the ratio of Escherichia coli and Salmonella is 60: 40, bird inlay is regularly strengthened injection, after the nursing of a period of time, hen lays eggs that the egg yolk of getting dilutes, flocculation, centrifugal filtration, ultrafiltration, microfiltration, lyophilization form.
Described complex is a crystalline solid, is baby pink, free from extraneous odour.Wherein:
The effect of anti-enterotoxin immunoglobulin: can coagulation, engulf and in and antibacterial and eliminating toxin composition, can kill or suppress common pathogenic entero becteria, as staphylococcus aureus, bacillus pyocyaneus, streptococcus, Salmonella;
The effect of ovotransferrin: can promote lymphocytic growth, prevent or suppress the pathogenic bacterium intrusion, can regulate and promote the bifidobacterium breve growth, can in conjunction with and carry iron ion, thereby the promotion infant effectively prevents anemia to the absorption of ferrum; Can suppress the generation of interior free yl, have the antidotal effect of alleviating rheumatoid arthritis;
The effect of lysozyme: preventing enteritis and allergy effect, is the bacillus bifidus growth factor, and the intestinal microbial population of infant is had balanced action; Has the effect of decomposing gram positive bacteria; Effect with caries prevention is the very high food antibacterial of a kind of safety.
Complex of the present invention, its total protein content can be up to 90%, and various amino acid contents are by (100 gram these complex amino acid contained gram number) shown in the table 1:
Table 1
| The aminoacid title | Content (g/100g) |
| It six winters propylhomoserin | ?????9.48 |
| Threonine | ?????4.36 |
| Serine | ?????5.80 |
| Glutamic acid | ?????12.21 |
| Glycine | ?????3.05 |
| Alanine | ?????5.26 |
| Cystine | ?????3.59 |
| Valine | ?????6.00 |
| Methionine | ?????3.26 |
| Isoleucine | ?????3.77 |
| Leucine | ?????7.04 |
| Tyrosine | ?????3.52 |
| Phenylalanine | ?????3.81 |
| Lysine | ?????6.88 |
| Histidine | ?????2.47 |
| Arginine | ?????4.42 |
| Tryptophan | ?????0.89 |
| Proline | ?????4.17 |
| Total amino acids | ?????89.98 |
The contained trace element of complex of the present invention is by (every kilogram complex contained milligram number) shown in the table 2:
Table 2
| Composition | Content (mg/kg) |
| ????Co | ?????0.062 |
| ????Cd | ?????0.032 |
| ????Mg | ?????145 |
| ????Cu | ?????3.47 |
| ????Zn | ?????10.6 |
| ????Fe | ?????42.7 |
| ????Pb | ?????0.036 |
| ????Cr | ?????2.38 |
Complex of the present invention owing to be rich in anti-enterotoxin immunoglobulin, so have the antibody of anti-enterotoxin, again owing to contain ovotransferrin and lysozyme, and have tangible gathering antibacterial with the effect of engulfing antibacterial.The main effect and the effect of this bright complex: can suppress the pathogenic bacterial strains in the human body intestinal canal, and it is had phagocytosis; Effect with treatment diarrhoea and enteritis improves the disease resistance ability of human body effectively; Complex of the present invention has no side effect, no hormone, and human body does not have any dependency to this product, is the activated protein that human body obtains the protectiveness passive immunity.
This product usage: the baby directly reconstitutes oral, and child, adult take after the meal or behind the full abdomen, exempt to reconstitute with hot water more than 50 ℃, avoid mixing with strong acid, highly basic.
Claims (5)
1, immunoactive yolk-albumen composition is characterized in that containing following component: anti-enterotoxin immunoglobulin, ovotransferrin and lysozyme.
2, complex as claimed in claim 1 is characterized in that containing in this complex gross weight moisture, ash and the trace element of anti-enterotoxin immunoglobulin 45～55%, ovotransferrin 17～23%, lysozyme 17～23% and surplus.
3, complex as claimed in claim 1 is characterized in that containing in this complex gross weight moisture, ash and the trace element of anti-enterotoxin immunoglobulin 50%, ovotransferrin 20%, lysozyme 20% and surplus.
4, as claim 1,2 or 3 described complex, it is characterized in that described anti-its molecular weight of enterotoxin immunoglobulin is 172KD (1720000), is 2 heavy chain H and 2 light chain L, becomes the Y font, light chain L molecular weight～23KD (230000) wherein, heavy chain H molecular weight～63KD (630000).
5, complex as claimed in claim 4, it is characterized in that this complex produces through the method: adopt the cell bacterium of enterotoxin class to make antigen, be prepared into vaccine, the ratio of Escherichia coli and Salmonella is 60: 40, bird inlay is regularly strengthened injection, after the nursing of a period of time, hen lays eggs that the egg yolk of getting dilutes, flocculation, centrifugal filtration, ultrafiltration, microfiltration, lyophilization form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00125941 CN1340360A (en) | 2000-08-31 | 2000-08-31 | Immunoactive yolk-albumen composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00125941 CN1340360A (en) | 2000-08-31 | 2000-08-31 | Immunoactive yolk-albumen composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1340360A true CN1340360A (en) | 2002-03-20 |
Family
ID=4591705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00125941 Pending CN1340360A (en) | 2000-08-31 | 2000-08-31 | Immunoactive yolk-albumen composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1340360A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101605453B (en) * | 2007-02-15 | 2011-10-26 | 国立大学法人冈山大学 | Pest control using lysozyme, its salts or biological fragments, or lysozyme-related peptides as egg recognition pheromones |
| CN111803628A (en) * | 2020-07-24 | 2020-10-23 | 尤丽康（江苏）生物医药有限公司 | Helicobacter pylori resisting compound preparation |
-
2000
- 2000-08-31 CN CN 00125941 patent/CN1340360A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101605453B (en) * | 2007-02-15 | 2011-10-26 | 国立大学法人冈山大学 | Pest control using lysozyme, its salts or biological fragments, or lysozyme-related peptides as egg recognition pheromones |
| CN111803628A (en) * | 2020-07-24 | 2020-10-23 | 尤丽康（江苏）生物医药有限公司 | Helicobacter pylori resisting compound preparation |
| CN111803628B (en) * | 2020-07-24 | 2021-05-14 | 尤丽康（江苏）生物医药有限公司 | Helicobacter pylori resisting compound preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106721843B (en) | Double-bacterial protein solid beverage | |
| TWI622352B (en) | Composition comprising heat labile milk proteins and process for preparing same | |
| CN102781460A (en) | Agent for preventing muscular atrophy | |
| CN114480549B (en) | Bioactive peptide prepared from snail, and preparation method and application thereof | |
| CN102264379A (en) | Muscle-strengthening agent | |
| AU657763B2 (en) | Trace element-rich additive, method for preparing same, preparation in which the additive is included and use thereof | |
| CN110637942A (en) | Laying hen premix rich in amino acid eggs and production method and application thereof | |
| JPH01221319A (en) | Composition for promoting enteral colonization -of useful bacteria and method therefor | |
| CN105876141A (en) | Feed added with protein-mulberry leaf additive for reducing cholesterol contents of livestock meat, poultry meat and eggs as well as preparation method thereof | |
| CN103815018A (en) | Yak yoghourt and preparation method thereof | |
| CN1340360A (en) | Immunoactive yolk-albumen composition | |
| KR20200058174A (en) | Manufacture method of spirulina extracts | |
| CN112136992A (en) | Milk-derived polypeptide compound protein beverage formula for reducing pressure and promoting sleep | |
| KR102534536B1 (en) | Composition and manufacturing method effective for antibacterial, antioxidant, and immunity enhancement using Probiotics Lactobacillus and red ginseng in the intestine of companion animal | |
| CN112961895B (en) | Black food fermentation type composite small molecular peptide, oral liquid, preparation method and application | |
| JPH06247871A (en) | Growth promoter | |
| JP3789146B2 (en) | Oligosaccharide-containing nutritional composition | |
| JPH11127815A (en) | Health maintenance by combination of certain oligosaccharides and microbial fermented tea | |
| CN101564174A (en) | Protein powder corrected by humanized amino acid spectrum | |
| JPH04365444A (en) | Antiallergic formulated milk | |
| CN113558148B (en) | Snow swallow product for cats as well as preparation method and application thereof | |
| KR20080054912A (en) | Improved gut function | |
| RU2366263C2 (en) | Broth with preventive properties, containing protein hydrolisate and protein hydrolisate production method | |
| RU2058081C1 (en) | Method of dairy product production for child nutrition | |
| JP2003113087A (en) | Oligosaccharide-containing nutrient composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |